Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
Resistant hypertension (RH) accounted for a considerable proportion of patients with
hypertension. It has been revealed to impose certain adverse effects on the prognosis of
patients with cardiovascular diseases. The antihypertensive effect of sacubitril/valsartan
being fully confirmed in previous studies, there were no related randomized controlled trials
(RCT) about this potency among Chinese patients with RH. The investigators designed this
study to evaluated effects and safety of sacubitril/valsartan versus valsartan on Chinese
patients with RH.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Treatments:
Amlodipine Hydrochlorothiazide Sacubitril and valsartan sodium hydrate drug combination Spironolactone Valsartan